Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

orion corporation - ropiniroli hydrochloride - dopaminergiset aineet, dopamiini-agonistit - koirat - induktio oksentelu koirilla.

Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

orion corporation - levodopa, karbidopa, entakaponi - parkinsonin tauti - parkinson-lääkkeet - corbilta on tarkoitettu hoito aikuispotilailla, joilla on parkinsonin tauti ja lopulta annoksen motor vaihtelut ole vakaa levodopa/dopa dekarboksylaasin (ddc) estäjä hoitoa.

Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

orion corporation - levodopa, karbidopa, entakaponi - parkinsonin tauti - hermosto - levodopa, carbidopa, entacapone orion on tarkoitettu hoito aikuispotilailla, joilla on parkinsonin tauti ja lopulta annoksen motor vaihtelut ole vakaa levodopa / dopa-dekarboksylaasin (ddc)-estäjä hoitoa.

Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

orion corporation - levodopa, karbidopa, entakaponi - parkinsonin tauti - parkinson-lääkkeet - stalevo on tarkoitettu hoidettaessa aikuispotilailla, joilla on parkinsonin tauti ja annoksen lopussa olevat moottorin heilahtelut, joita ei ole stabiloitu levodopa / dopa-dekarboksylaasi (ddc) -inhibitorin hoitoon.

Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - dermatiittiautia lukuun ottamatta kortikosteroideja - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

orion corporation - dexmedetomidine hydrochloride - psyykenlääkkeiden - dogs; cats - ei-invasiiviset, lievästi tai kohtalaisesti kivulias, menettelyt ja tutkimukset, jotka edellyttävät koirien ja kissojen turvaamista, sedaatiota ja analgesiaa. preediaatio kissoilla ennen ketamiinin yleisen anestesian induktiota ja ylläpitoa. deep sedaatio ja analgesia koirilla samanaikaisessa käytössä butorfanolin kanssa lääketieteellisten ja vähäisten kirurgisten toimenpiteiden kanssa. koirien esilääkitys ennen yleisen anestesian induktiota ja ylläpitoa.

Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belantamab mafodotin - multiple myeloma - antineoplastiset aineet - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

pfizer europe ma eeig - batsedoksifeenia - osteoporoosi, postmenopausaalinen - sukupuolihormonit ja genitaalijärjestelmään vaikuttavat aineet, - conbriza on tarkoitettu postmenopausaalisen osteoporoosin hoitoon naisilla, joilla on lisääntynyt murtumisvaara. sääriluiden murtumien esiintyvyys on merkittävästi pienentynyt; tehoa lonkkamurtumissa ei ole osoitettu. määritettäessä valinta conbriza tai muita hoitoja, kuten estrogeenit, yksittäisen postmenopausaalista naista, on otettava huomioon vaihdevuosien oireita, vaikutuksia kohdun ja rintojen kudosten ja sydän-riskit ja hyödyt.

Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

opk biotech netherlands bv - hemoglobiini glutameeri-200 (naudat) - veren korvikkeet ja perfuusioliuokset - koirat - oxyglobin tarjoaa happea kantavaa tukea koirille, jotka parantavat anemian kliinisiä oireita vähintään 24 tunnin ajan, riippumatta taustalla olevasta tilasta.

Phần Lan - Tiếng Phần Lan - Fimea (Suomen lääkevirasto)

stada arzneimittel ag - timolol maleate, travoprost - silmätipat, liuos - 40 mikrog/ml + 5 mg/ml - timololi